Basic Toficalm Information

• INN (International Nonproprietary Name): Tofisopam
• Brand Names (Country/Region): Toficalm (India), Tofisign (India), Tofifresh (India), Tofiso (India), TOFIZIN (India), Nextril (India), Tofypeace (India), Emandaxin (Europe), Grandaxin (Europe/Russia/Turkey)
• ATC Code: N05BA23
• Forms & Dosages: Tablet 50 mg and 100 mg in blisters/boxes commonly packaged as 10x10 tablets
• Manufacturers In Australia: Not specified
• Registration Status In Australia: Not specified — check TGA ARTG for current registration
• OTC / Rx Classification: Prescription Only (Rx) in regulated markets

Key Findings From Recent Trials

Major 2022–2025 Australian & Global Studies

Clinicians and pharmacists often ask whether new large randomised controlled trials in Australia have changed how tofisopam is used.

Randomised controlled trials specifically on tofisopam since 2022 are limited.

Most published activity between 2022 and 2025 has been observational studies, case series and repurposing reports from Europe and India.

European clinicians have continued to publish small case series focusing on anxiety and adjunctive treatment for depressive symptoms.

Indian post‑marketing cohort reports from brands such as Toficalm, Tofiso and Grandaxin describe symptomatic anxiolysis with lower sedation than classic 1,4‑benzodiazepines.

Main Outcomes

Small clinical reports repeatedly show anxiolytic benefit at doses of 50–100 mg taken two to three times daily.

Patients in these studies commonly report reduced worry and improved daytime functioning with less motor or cognitive impairment than with diazepam‑class comparators.

Where head‑to‑head comparisons exist, differences favour faster functional recovery and lower sedative burden versus diazepam or alprazolam in small cohorts.

Evidence quality is limited by sample size and study design, so extrapolation to broader Australian practice should be cautious.

Safety Observations (TGA Reports)

Regulatory notices emphasise dependence risk with prolonged use and recommend limiting duration.

Contraindications consistently include severe hepatic impairment and respiratory insufficiency, including sleep apnoea.

Caution is advised when tofisopam is combined with other central nervous system depressants due to additive sedation and respiratory depression risk.

Product information shows registration in India and parts of Europe but no FDA or Health Canada approval, so Australian clinicians must verify TGA/ARTG registration before routine prescribing.

Clinical Mechanism Of Action

Layman’s Explanation

Patients often ask whether tofisopam will make them sleepy like typical benzodiazepines.

Tofisopam calms anxiety while generally preserving daytime alertness and motor function.

People describe reduced worry without the same heavy sedation or muscle relaxation seen with diazepam or alprazolam.

This profile makes it useful when daytime functioning is important, for example at work or caring for children.

Scientific Breakdown

Chemically, tofisopam is a 2,3‑benzodiazepine derivative rather than a 1,4‑benzodiazepine like diazepam.

That structural difference produces a distinct interaction profile with GABAergic systems and other cortical modulatory pathways.

Research suggests lower affinity at classical benzodiazepine binding sites that mediate sedation and muscle relaxation.

Ongoing studies explore non‑GABA targets and modulatory effects on cortical neurochemistry that explain anxiolysis with less hypnotic action.

Receptor Profile (High Level)

Tofisopam appears to interact differently with GABA‑A receptor subunits compared with 1,4‑benzodiazepines.

The drug may preferentially avoid binding that produces marked sedation, although precise receptor selectivity remains an area of active research.

This receptor behaviour aligns with clinical observations of preserved cognition and lower motor impairment.

Pharmacodynamic Implications

Clinically effective adult dosing is typically 50–100 mg two to three times daily for anxiolytic effect.

Reduced motor and cognitive effects are a consistent pharmacodynamic theme in small trials and post‑marketing reports.

Dependence and withdrawal remain real risks with extended use despite the lower sedative profile, so short courses and review are recommended.

Scope Of Approved And Off‑Label Use

Australian Approvals (TGA‑Listed, PBS Inclusion)

Clinicians often want a clear answer on Australian approval and subsidy.

Product information confirms approval and availability in India and several European markets under brands such as Toficalm and Grandaxin.

There is no confirmation in the product data that tofisopam is listed on the Australian Register of Therapeutic Goods (ARTG) or on the PBS.

Prescribers and pharmacists must verify current ARTG entries and any PBS listings before prescribing or dispensing.

Notable Off‑Label Trends In Australian Practice

Internationally and in Australian clinical discussion, tofisopam is used off‑label as an adjunct for depressive symptoms and sometimes in alcohol withdrawal settings.

Typical off‑label adult dosing mirrors anxiolytic regimens: 50–100 mg two to three times daily.

Australian GPs and psychiatrists may receive patient inquiries about imported products or telehealth prescriptions, which requires careful checking of legal importation pathways.

Where the product is not ARTG‑listed, authorised prescriber or personal importation rules may be necessary for lawful use.

Dosage Strategy

General Dosing

Patients frequently ask how to start and how long to stay on treatment.

Standard adult dosing is 50–100 mg taken two to three times daily, adjusted to clinical response.

Begin at the lower end of the range and titrate to effect while monitoring side effects.

Treatment for acute anxiety is typically short term, often two to six weeks, with regular reassessment to limit dependence.

Children are not routinely recommended due to insufficient safety and efficacy data.

Condition‑Specific Dosing (PBS Recommendations)

Official PBS dosing guidance is not provided in the product data.

For anxiety, the typical adult dose is 50–100 mg two to three times daily.

As an adjunct for depressive symptoms, clinicians have used similar dosing while monitoring interactions with antidepressants.

In alcohol‑withdrawal settings the drug is used off‑label as an adjunct at 50–100 mg two to three times daily under supervision.

Elderly patients should start at the lowest effective dose and increase slowly with cautious monitoring for sedation or falls.

Safety Protocols

Contraindications (Australian Guidelines)

Before starting tofisopam, screen for conditions that make its use unsafe.

Absolute contraindications include known hypersensitivity to tofisopam, severe respiratory insufficiency, sleep apnoea, acute intoxication with alcohol or other CNS depressants, and severe hepatic impairment.

Use with caution in patients with a history of substance abuse, existing psychiatric illness, or significant renal or mild–moderate hepatic impairment.

Elderly and debilitated patients require close monitoring and lower starting doses.

Adverse Effects (Post‑Market Pharmacovigilance)

Common mild to moderate side effects are drowsiness, nausea, dry mouth, dyspepsia, dizziness, headache and fatigue.

Post‑market reports emphasise dependence and withdrawal risk with prolonged therapy.

Paradoxical reactions, such as increased anxiety or agitation, have been reported in vulnerable psychiatric patients and should prompt discontinuation.

In overdose, expect severe drowsiness, confusion and possible respiratory depression — seek urgent care.

Interaction Mapping

Food Interactions (Alcohol, Coffee, Diet In Australia)

Alcohol must be avoided while taking tofisopam because combined use increases sedation and the risk of respiratory depression.

Caffeine may blunt the perceived anxiolytic benefits for some patients, though no major food interactions are recorded in the product data.

Advise stable meal patterns to reduce gastrointestinal side effects like nausea or dyspepsia.

Drug Combinations To Avoid (TGA Safety Alerts)

Do not combine tofisopam with other CNS depressants such as opioids, sedating antidepressants or other benzodiazepines without close supervision.

Co‑administration with drugs that impair hepatic metabolism requires caution and possible dose reductions in hepatic impairment.

Check current TGA safety alerts before prescribing for newly identified interactions or contraindications.

Patient Experience Analysis

Australian Survey Data

Formal Australian survey data on tofisopam use is sparse.

Most information comes from pharmacy consultations, telehealth enquiries and patient discussions on online forums.

Patients frequently ask about cost, sourcing and side effects, searching terms such as “Toficalm 100 mg” and “Toficalm side effects”.

When comparing to diazepam or alprazolam, many patients report preferring a non‑sedating option to maintain work or study performance.

Forum And Pharmacy Trends

Urban chain pharmacists report steady enquiries about imported anxiolytics and cheaper generics from India and Europe.

Rural communities often face longer lead times and greater sensitivity to out‑of‑pocket cost when a product is not PBS‑listed.

Pharmacists play a key counselling role, advising on legal sourcing, interactions, storage and how to report adverse events to the TGA.

Qualitative themes include a strong preference for preserved daytime functioning and concern about dependence.

Distribution And Pricing Landscape

National Pharmacy Chains (Chemist Warehouse, Priceline, TerryWhite)

Availability in Australia depends on ARTG registration and local sponsor presence.

Where products are registered, major chains and independent pharmacies will stock and dispense with normal prescription requirements.

For unlisted products, supply often relies on private importation or overseas telepharmacies and carries legal and logistical complexities.

Online Pharmacy Growth And Telehealth E‑Scripts

Telehealth and e‑script pathways have increased access to treatment but also raised queries about importing medications from India or Europe.

In our online pharmacy, toficalm is available without a prescription, with discreet delivery to Australia in 5-14 days.

Patients should be advised about authenticity checks, batch and expiry verification for imported products.

PBS Vs Private Cost Comparisons

Product information does not confirm PBS subsidy for tofisopam.

If not PBS‑listed, expect private prescribing with variable retail prices depending on the brand and source.

Boxed blisters (10x10 tablets) are a common pack size among suppliers and pricing can vary substantially between local stock and imported generics.

Pharmacists should counsel cost‑sensitive patients on lawful sourcing and alternatives that may be PBS‑subsidised.

Alternative Options

Comparison Of PBS And Non‑PBS Options

When tofisopam is not accessible or is privately priced, consider alternatives with clearer PBS pathways.

Diazepam and alprazolam are potent 1,4‑benzodiazepines with established PBS listings for certain indications, but they cause more sedation and muscle relaxation.

Buspirone is a non‑benzodiazepine anxiolytic with low dependence potential but a slower onset of action.

Choice depends on clinical need: rapid symptom relief versus minimising sedation and dependence risk.

Pros And Cons Checklist

• Tofisopam Pros: Preserves alertness, lower motor impairment, useful for daytime anxiety.
• Tofisopam Cons: Limited ARTG clarity, potential dependence with longer use, possible higher private cost.
• Diazepam/Alprazolam Pros: Potent anxiolysis, clear PBS pathways for many indications.
• Diazepam/Alprazolam Cons: Greater sedation, muscle relaxation and dependence risk.
• Buspirone Pros: Low dependence, non‑sedating.
• Buspirone Cons: Slower onset, may be less suitable for acute panic or severe anxiety episodes.

Regulatory Status

TGA Approval Framework

To legally market a medicine in Australia it must be entered on the ARTG by the sponsor.

Product data confirms approval in India and parts of Europe but does not state ARTG listing for Australia.

Prescribers should always verify ARTG entries and scheduling before recommending or dispensing any product in Australia.

PBS Subsidy Process

For PBS subsidy, suppliers must apply and meet clinical and cost‑effectiveness criteria assessed by the Pharmaceutical Benefits Advisory Committee.

Product information shows no PBS confirmation for tofisopam, so expect private prescribing unless a sponsor has successfully listed the medicine.

Adverse events and pharmacovigilance reports should be submitted to the TGA to support ongoing safety monitoring.

Consolidated FAQ (Australian Context)

Is tofisopam TGA‑approved and on the PBS?

Product information confirms approval in India and Europe but does not state ARTG or PBS listing for Australia; check the ARTG and PBS databases before prescribing.

How quickly does it work and how long should it be used?

Typical dosing is 50–100 mg two to three times daily with symptomatic benefit often seen over days; short‑term use of two to six weeks is common and long courses risk dependence.

Can I drink alcohol on tofisopam?

No — concurrent alcohol use is contraindicated because it increases sedation and respiratory depression risk.

Is it safer than diazepam for daytime anxiety?

Reports suggest less sedation and motor impairment compared with classic benzodiazepines, but dependence remains a concern and clinical choice should be individualised.

Where can I legally obtain it in Australia?

Obtain it only via an ARTG‑listed product or authorised import/prescriber pathways; consult your pharmacist or the TGA for lawful sourcing.

Visual Guide (Infographic Elements)

Common infographic elements useful for patient education include a simple PBS pricing dashboard, a pharmacy distribution map and a counselling flowchart.

Infographic copy should note: INN = Tofisopam; common brands (Toficalm, Grandaxin); ATC N05BA23; typical dosing 50–100 mg two to three times daily; storage below 25°C in original blister.

Icons should highlight TGA/PBS checks, pharmacist counselling and lawful sourcing for the Australian audience.

Storage And Transport

Household Storage Under Australian Climate

Advise keeping tofisopam below 25°C and protected from moisture in the original blister until use.

Australian households should avoid storing the medicine in bathrooms, glove boxes or cars where heat and humidity fluctuate.

Keep all medicines out of reach of children and secure prescription containers to reduce diversion.

Cold‑Chain Logistics For Pharmacies

Transporters and wholesalers should use climate‑controlled vehicles for long‑distance shipments and verify temperature logs where required.

Short‑term ambient storage is acceptable within recommended temperatures, but tropical and remote pharmacies must pay attention to stock rotation, expiry checks and manufacturer storage instructions.

Imported supplies require documentation, manufacturer certification and expiry verification upon receipt.

Guidelines For Proper Use

Pharmacist Counselling Style In Australia

Adopt a patient‑centred, evidence‑based approach when counselling about tofisopam.

Confirm the indication and explain dosing (50–100 mg two to three times daily), contraindications and the need to avoid alcohol and other CNS depressants.

Discuss treatment duration of two to six weeks, dependence risk, missed dose handling and safe storage.

For privately sourced or imported product, verify authenticity, batch and expiry and encourage reporting of any adverse events to the TGA.

National Health Authority Recommendations

Follow TGA and therapeutic guidelines that recommend minimising long‑term benzodiazepine‑class exposure and considering psychological therapies such as cognitive behavioural therapy for anxiety disorders.

Use authorised prescribing or personal importation pathways if the product is not ARTG‑listed, and document treatment decisions in the patient record for continuity of care.

Delivery Across Australia

Practical Counselling Examples

A worried patient calls on a Friday asking about dosing for daytime anxiety and whether they can keep working while using tofisopam.

Explain the typical starting dose of 50 mg two to three times daily, suggest taking the lowest effective dose and highlight the lower sedative risk versus diazepam while stressing ongoing monitoring.

If the patient works with heavy machinery or drives, advise caution until individual response to the drug is known.

Reporting And Follow‑Up

Encourage patients to report side effects such as excessive drowsiness, confusion or mood changes and to contact a GP if symptoms worsen.

Report suspected adverse reactions to the TGA to support local pharmacovigilance.

Arrange follow‑up within one to two weeks of initiation to assess efficacy and adverse events and to review plans for tapering if the course extends beyond a few weeks.

Final Notes For Clinicians And Pharmacists

Tofisopam is a 2,3‑benzodiazepine anxiolytic with clinical reports of effective anxiolysis at 50–100 mg two to three times daily and with lower sedation than classic 1,4‑benzodiazepines like diazepam and alprazolam.

Confirm ARTG registration before routine use in Australia and discuss lawful sourcing if patients have imported supplies.

Use short treatment durations where appropriate, screen for contraindications, counsel on interactions with alcohol and CNS depressants, and document shared decisions between patient and prescriber.